Search | Clinical Trials Finder

Conditions: Early Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more

Conditions: Bipolar Disorder I or II With a Major Depressive Episode
Interventions: ALTO-100, Placebo; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 27
States / cities: Chandler, Arizona • Phoenix, Arizona • Yuma, Arizona + 22 more

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Parkinson's Disease, Depression
Interventions: SAM-e, oral escitalopram, placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 30 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Homeostasis, Bone and Bones
Interventions: Dexlansoprazole, Esomeprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 75 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years to 16 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more

Conditions: Hypertension
Interventions: Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 88
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more

Conditions: Low Back Pain
Interventions: Intra-articular corticosteroid injection, Intra-articular saline injection; Drug
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more

Conditions: Differentiated Thyroid Cancer
Interventions: Vandetanib (SAR390530), Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Torrance, California • Lexington, Kentucky + 7 more

Conditions: Ulcerative Colitis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 25
States / cities: Dothan, Alabama • Los Angeles, California • Bristol, Connecticut + 21 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Ritalin LA (methylphenidate hydrochloride extended release); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more

Conditions: Alzheimer's Disease
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 72 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Fitchburg, Wisconsin

Conditions: Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tachycardia, Chronic Orthostatic Intolerance
Interventions: Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder; Drug · Other · Dietary Supplement + 3 more
Lead sponsor: Satish R. Raj; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Social Phobia
Interventions: Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo; Behavioral · Drug
Lead sponsor: University of Central Florida; Other
Eligibility: 8 Years to 16 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: University of Maryland, College Park, Maryland

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Healthy
Interventions: PF-04995274; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ulcerative Colitis (UC)
Interventions: Adalimumab, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: PE0139 Injection, Placebo; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anniston, Alabama • Hialeah, Florida • Renton, Washington

Conditions: Liver Cirrhosis
Interventions: Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more

Search by objective public record fields.

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

ALTO-100 in Bipolar Disorder With Depression (BD-D)

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

Effect of Dexlansoprazole on Bone Homeostasis

Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

Treatment of Orthostatic Intolerance

Treatment of Childhood Social Phobia

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis